SEC Filing Summary: Pro-Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pro-Pharmaceuticals, Inc. on December 20, 2006. The filing reports a corporate governance event regarding the appointment of a new member to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
On December 20, 2006, the Company's Board of Directors appointed James T. Gourzis, M.D., Ph.D., to serve as a member of the Board until the 2007 annual meeting of stockholders. Dr. Gourzis brings extensive experience in scientific, strategic, and regulatory considerations for drug and biologic development, having served as Principal at MEDRAND Associates since 2002 and previously held senior roles at PAREXEL International Corporation, Gensia Pharmaceutical, Inc., and Hill Top Pharmatest, Inc.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to the announcement of the board appointment.
Key Facts for Investor Verification
- James T. Gourzis, M.D., Ph.D., was appointed to the Board of Directors effective December 20, 2006.
- Dr. Gourzis's term is set to last until the 2007 annual meeting of stockholders.
- The filing includes a news release dated December 20, 2006, as Exhibit 99.1.
- No financial data or operational metrics are disclosed in this specific 8-K filing.